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SUMMARY 
 
Free sialic acid storage diseases, Salla disease (SD) (OMIM 604369) and the 
allelic form infantile sialic acid storage disease (ISSD) (OMIM 269920), are 
autosomal recessively inherited neurodegenerative disorders. They are 
characterized by lysosomal accumulation of free sialic acid. The biochemical 
defect underlying these diseases is deficient transport of free sialic acid from 
lysosomes. Salla disease is enriched in the Finnish population and hence, is part 
of the Finnish disease heritage.  
 
Using genome-wide scan and linkage analysis, the locus for SD was in 1994 
mapped to chromosome 6q14-q15, the critical region was further refined and a 
physical map constructed. This was the setting for the present thesis. Across 
species comparisons of ESTs (Expressed Sequence Tags) in the critical region 
led to identification of a new gene, SLC17A5. The protein encoded by 
SLC17A5, designated sialin, was predicted to be a transmembrane protein and 
showed homology to a family of anion/cation symporters (ACS). Mutations 
were found in this gene in patients both with SD and with ISSD.  
 
A founder mutation, SallaFIN, was identified in all Finnish SD patients. The 
majority of the Salla patients are homozygous for SallaFIN and they present with 
a classical SD phenotype characterized by early onset developmental delay and 
ataxia. SallaFIN was also found in heterozygous form in Finnish and in a few 
foreign patients, typically representing a more severe phenotype. A spectrum of 
mutations, but never SallaFIN, was detected in patients with the most severe 
phenotype, ISSD.  
   11
The expected lysosomal localization of sialin was confirmed by subcellular 
fractionation. Sialin was also localized to lysosomes in various transiently 
transfected non-neuronal cell lines by immunofluorescence microscopy. The 
SallaFIN and ISSD polypeptides showed altered intracellular targeting. The 
majority of the ISSD and a fraction of the SallaFIN polypeptides were retained in 
the Golgi. Furthermore, the trafficking of the mutant polypeptides to lysosomes 
was significantly slower when compared to the wild-type sialin, the ISSD 
mutant polypeptides showing the slowest transport. Thus, the severity of the 
intracellular targeting defect seemed to parallel the functional defect in vivo: SD 
presents with mental retardation and a long life expectation, while ISSD is an 
early fatal disorder. 
 
The analyses of the spatial expression of sialin in mouse brain and the 
localization of the protein in neurons and glia revealed that, in the CNS, sialin 
was predominantly expressed in neurons, especially in the prospective 
neocortex and the hippocampus of the developing brain. In primary glial cell 
cultures, as in non-neuronal cells, sialin was localized to lysosomes, whereas in 
neuronal cultures, the expression was observed along the neurites and also in 
the plasma membrane. This non-lysosomal localization of sialin could suggest a 
role for sialin in the secretory processes of neuronal cells, potentially having 
implications for the molecular background of the CNS symptoms in Salla 
disease and ISSD.   12
REVIEW OF THE LITERATURE 
 
1. Current era in identification of human disease genes 
1.1. The Human Genome Project 
The systematic international efforts of the Human Genome Project (HGP) 
started in 1990 and led to the complete, high-quality sequence of the human 
genome in April 2003, 50 years after the discovery of the structure of DNA 
(Watson and Crick 1953). The finished sequence covers about 99% of the 
human genome’s gene-containing (euchromatin) regions. The estimated number 
of genes is less than 30,000, which is much lower than was previously thought 
(http://www.ornl.gov/TechResources/Human_Genome/project/info.html). 
Surprisingly, the coding sequences make up only about 2% of the whole 
genome. Repeated sequences that do not code for proteins are likely to account 
for at least 50% of the remaining non-coding DNA. The precise genome 
information provides fundamental tools for scientists in molecular genetics and 
biomedical research to find as yet uncharacterized genes and to understand their 
function(s) and role(s) in health and disease. Huge challenges still remain, since 
the non-coding part of the genome (heterochromatin) is likely to be functionally 
important but as yet very little is known about it. Genome projects of various 
species have produced complete sequences of the genomes of several other 
organisms including the baker’s yeast Saccharomyces Cerevisae (Goffeau et al. 
1996), the roundworm Caenorhabditis elegans (Consortium 1998), the fruitfly 
Drosophila melanogaster (Myers et al. 2000) and the mustard cress Arabidopsis 
thaliana ((AGI) 2000). A draft sequence of the mouse Mus musculus genome, 
probably the most important model organism for human genetic studies, was 
published at the end of the year 2002 (Waterston et al. 2002). All these   13
sequences are currently easily accessible in the databases facilitating genome-
wide annotation of any biological function or trait. 
 
1.2. Identification of human disease genes 
To date, the causative gene has been identified and sequenced for 1541 of the 
approximately 6000 known inherited human diseases 
(http://www.ncbi.nlm.nih.gov/LocusLink). There are several different strategies 
for identifying disease genes: functional cloning, positional cloning, the 
positional candidate gene approach and the position-independent candidate gene 
approach.  
If the precise biochemical defect underlying the disease is known and purified 
protein is available, a functional cloning approach can be used to characterize 
the gene. The complete or partial protein sequence can be obtained by amino 
acid sequencing followed by screening of cDNA libraries either with antibodies 
or degenerate oligonucleotides. The classical examples of a successfully 
employed functional cloning approach include identification of the gene 
encoding the enzyme phenylalanine hydroxylase (PAH) in phenylketonuria and 
of mutations in coagulation factor VIII gene in hemophilia A patients (Robson 
et al. 1982; Gitschier et al. 1984). The position-independent candidate gene 
approach is based exclusively on the molecular pathology of the disease or the 
phenotypically related diseases and seldom gives the desired result. 
The prerequisite for using the positional cloning method and the positional 
candidate gene approach is knowledge of the chromosomal region to which the 
disease locus has been mapped, i.e. the position of the gene in the genome 
(Collins 1992; Collins 1995). Hence, it starts with collecting families in which 
the disease segregates, followed by linkage analysis to determine the specific 
chromosomal localization of the disease gene (Ott 1991; Terwillinger and Ott   14
1994). Especially in isolated populations, such as Finland, this region can then 
be refined using haplotype analysis and linkage disequilibrium (Hastbacka et al. 
1992; Hastbacka et al. 1994; Peltonen et al. 1995). In the pre-genome era, the 
next step was to cover the critical region with overlapping genomic clones 
(YACs, BACs and cosmids) (Figure 1). Then several methods could be used to 
isolate the DNA, identify the transcripts, clone the cDNA and finally identify 
the disease-causing mutations.  
 
 
 
Figure 1: Steps in identification of a disease gene before and after the availability of sequence 
information produced by HGP. 
 
As a result of the HGP, the cloning of human disease genes has changed 
dramatically. With the available sequence data, disease genes is nowadays most 
often identified using a combined strategy of positional cloning and candidate 
gene approaches. When the disease locus has been identified, the positional 
candidates, known genes, ESTs, or predicted genes, in the region are selected 
on the basis of their known or presumed function and analyzed for mutations in   15
the patients. The fruits of HGP have thus made it possible to skip the laborious 
phase in a positional cloning process, the construction of the physical map and 
the isolation of genes within the region of interest (Figure 1). At the time of the 
announcement of the first draft sequence of the human genome, at least 30 
disease genes had been positionally cloned depending directly on the publicly 
available draft genome sequence information (for review see (Lander et al. 
2001). Using bioinformatics, it is now also possible to make sequence 
comparisons between different species. This comparative genomics allows 
highly efficient identification of new genes as well as provides clues of the so 
far mostly uncharacterized regulatory regions of genes. Comparison of the 
human sequence and the sequence of model organisms has become a powerful 
tool in identifying human genes and in efforts to interpret their function.  
 
2. Free sialic acid storage disorders 
Free sialic acid storage disorders (SASD) are characterized by accumulation of 
free sialic acid either in the lysosomes or in the cytoplasm (Aula and Gahl 
2001). Sialic acids comprise a group of related compounds, all derived from 
neuraminic acid. The major sialic acid in humans is N-acetylneuraminic acid 
(NANA), which is a negatively charged monosaccharide added as the terminal 
sugar residue to oligosaccharides during the glycosylation process in the Golgi 
compartment. Oligosaccharide-bound sialic acids are involved in several 
metabolic functions, such as hormonal responses, neuronal signal transmission, 
immunological processes, tumourigenesis and cell adhesion (Grollman et al. 
1993; Traving and Schauer 1998). Upon degradation of sialoglycoconjugates in 
lysosomes, the enzyme α-neuraminidase catalyzes the removal of sialic acid 
residues which are subsequently transported to the cytosol either for   16
reutilization or for degradation by a cytosolic enzyme, N-acetyl lyase (Sommar 
and Ellis 1972; Renlund et al. 1983).  
The lysosomal free sialic acid storage diseases include the allelic disorders Salla 
disease (SD) (OMIM 604369) and infantile sialic acid storage disease (ISSD) 
(OMIM 269920), in which the transport of free sialic acid from lysosomes is 
defective (Renlund et al. 1986). The only cytoplasmic free sialic acid storage 
disease is sialuria, which is caused by loss of feedback inhibition of a key 
enzyme, UDP-GlcNAc 2-epimerase, in sialic acid synthesis (Seppala et al. 
1999). SD is mainly a disease of the Finnish population in which no cases of 
ISSD have been diagnosed. 
 
2.1. Salla Disease 
2.1.1. Genetic background of Salla disease  
Salla disease (SD) was first described in 1979 and named after the geographical 
region in the northeastern Finland, Salla, where the first patients were 
discovered (Aula et al. 1979). To date, 108 Finnish and approximately 30 non-
Finnish patients are known. SD is part of the Finnish disease heritage (FDH) 
which consists of 36 monogenic diseases enriched in the Finnish population 
(Nevanlinna 1972b; Nevanlinna 1972a; Norio 2003c; Norio 2003b; Norio 
2003a). The majority of these diseases, including Salla disease, are autosomal 
recessively inherited. FDH can be explained by the population history of 
Finland. The present population is derived from a small founding population 
which has undergone several bottlenecks during the growth and inhabitation of 
the country. This has resulted in losses and enrichments of disease-causing 
mutations. In addition, the influx of foreign genes has been limited up to the 
present time. Consequently, one founder mutation has been established in all 
the diseases of the Finnish disease heritage (Peltonen 1997; Peltonen et al.   17
1999). Salla disease is also encountered outside the borders of Finland, mainly 
in Sweden but rarely also in other European countries and in North America 
(Erikson et al. 2002; Martin et al. 2003). The common history of Finland and 
Sweden and the admixture of these populations are plausible explanations for 
the high incidence of SD in Sweden. 
The gene locus of Salla disease was mapped to chromosome 6q14-6q15 by 
genome-wide scan and linkage analysis in 27 Finnish SD families (Haataja et 
al. 1994b). The genetic position of the SD locus was further refined to an 
approximately 80 kb region using linkage disequilibrium (Schleutker et al. 
1995a). Haplotype analysis of Finnish SD patients suggested that one founder 
mutation accounts for the disease in Finnish patients. Similar studies in non-
Finnish patients with free sialic acid storage disease provided evidence for 
different mutations in patients from elsewhere (Schleutker et al. 1995b). A 
physical map was constructed over the critical chromosomal region harbouring 
the Salla disease locus (Leppanen et al. 1996). These studies formed a good 
starting point for the cloning efforts of the disease gene.  
 
2.1.2. Clinical phenotype 
The phenotypic variation in Salla disease is wide (Table 1) (Renlund et al. 
1983; Varho 2001). Most of the Finnish patients have a classical phenotype 
with a slowly progressing form of the disease. However, some patients are more 
severely affected and their phenotype is referred to as intermediate (Baumkotter 
et al. 1985; Ylitalo et al. 1986; Mancini et al. 1992b; Biancheri et al. 2002; 
Kleta et al. 2003). The clinical symptoms of Salla disease consist of moderate to 
severe psychomotor retardation and ataxia usually presenting before the age of 
one year. The progress of developmental delay is slow and degeneration 
becomes more pronounced during the second or third decade. All adult patients 
are profoundly mentally retarded, with IQs between 20 and 40. Most SD   18
patients learn to walk and speak words or short sentences, but a minority are 
more severely affected and are unable to walk independently. Patients affected 
with SD have a long life-span, the oldest patient died at the age of 72. All SD 
patients excrete large amounts of free sialic acid in their urine, 5 to 36 times the 
normal, and store it excessively in several types of tissue and in cultured 
fibroblasts (Renlund et al. 1986; Mancini et al. 1989). In electron microscopic 
(EM) studies, enlarged lysosomes can be seen in several organs, including the 
skin, muscle, nerve and liver and in various cell types (Aula et al. 1979; 
Wolburg-Buchholz et al. 1985; Echenne et al. 1986). Elevated sialic acid 
excretion has clinical significance, as it offers a basis for the clinical diagnosis. 
Magnetic resonance imaging (MRI) studies have shown defective myelination 
in the central nervous system (CNS) as well as a thin corpus callosum as a 
constant finding in SD patients (Haataja et al. 1994a; Autti et al. 1997; 
Sonninen et al. 1999). The results of a neuropathological study also showed 
marked loss of axons and myelin sheets in the CNS as well as axonal 
degeneration in the spinal cord (Autio-Harmainen et al. 1988). Interestingly, 
dysmyelination has also been observed in the peripheral nervous system in Salla 
disease (Varho et al. 2000). 
 
2.1.3. Biochemical defect 
Already two decades ago, the biochemical defect was proposed to be in the 
transport of sialic acid from lysosomes (Renlund et al. 1983). Studies on 
lysosomes isolated from SD patient fibroblasts showed that the sialic acid 
synthesis and the cleavage of exogenous glycoconjugates are normal, but free 
sialic acid cannot leave the lysosome (Renlund et al. 1986). Moreover, it was 
shown that the lysosomal transport of sialic acid was also defective in patients 
with ISSD and in patients with the intermediate phenotype (Mancini et al. 
1986). A proton-driven transporter specific for acidic monosaccharides,   19
including sialic and glucuronic acid, was later characterized in purified 
lysosomal membrane vesicles from rat liver (Mancini et al. 1989). The transport 
of these sugars was demonstrated to be defective in uptake studies using 
isolated lysosomal membrane vesicles from cultured fibroblasts of patients with 
different phenotypic presentations of SASD (Mancini et al. 1991). In the 
obligate heterozygotes, the transport rates were reduced. These results verified 
the deficient lysosomal sialic acid transport as the genetic defect in free sialic 
acid storage disorders.  
 
Type of disease  Hallmark clinical features  Age of onset  Free sialic 
acid  
in urine
1 
 SALLA  Hypotonia and ataxia, ocular squint, 
delayed development, few words, able 
to walk, IQ 20-30, lifespan near 
normal. 
6 – 12 months  12 fold 
(5-36) 
INTERMEDIATE  
“severe Salla”  Severe hypotonia, later ataxia, 
spasticity, growth delay, no 
organomegaly, seizures, shortened 
lifespan. 
1 – 6 months  15-34  
fold 
ISSD  Intrauterine hydrops, neonatal ascites, 
hepatosplenomegaly, dysmorphic 
features, failure to thrive, early death 
(<2 years). 
Intrauterine   102 fold 
(18-245) 
1 Mean of free sialic acid in normal controls: 58±19nM/mg creatinine (Aula and Gahl 2001) 
 
Table 1. Summary of clinical hallmark features in free sialic acid storage diseases. 
 
 
2.2. Infantile sialic acid storage disease 
At the other end of the phenotypic spectrum of lysosomal free sialic acid 
storage diseases are the ISSD patients (Hancock et al. 1982; Tondeur et al. 
1982). ISSD shows no ethnic clustering and the disease is very rare; there are 
fewer than 30 reported cases worldwide but none in Finland (reviewed by   20
Lemyre et al. 1999; Kleta et al. 2003). The course of the disease is much more 
severe than in Salla disease. The affected newborns exhibit coarse facial 
features, an enlarged liver and spleen, and failure to thrive right after birth. 
ISSD patients have a shortened lifespan, usually of less than two years. The 
urinary excretion of free sialic acid and the storage in fibroblasts is 18-245 
times higher in ISSD when compared to controls (Hancock et al. 1982). In EM 
studies, the lysosomal accumulation of sialic acid is seen in many tissues and 
cell types (Tondeur et al. 1982; Stevenson et al. 1983). 
 
3. Lysosomal membrane proteins 
3.1. Lysosomes 
Lysosomes are the main organelles responsible for protein degradation within 
cells. They are acidic, hydrolase-rich compartments enclosed by a membrane 
containing cholesterol, a characteristic composition of phospholipids and an 
abundance of carbohydrates (Bleistein et al. 1980; Lloyd and Forster 1986). 
Lysosomes were first identified by Christian de Duve in 1955 as a special type 
of cytoplasmic granule with an abundance of hydrolytic enzymes (De Duve et 
al. 1955). Since then, it has become clear that lysosomes have a more complex 
function than being the end-point on a degradative pathway. Many 
physiological processes, including the turnover of normal cellular proteins, 
downregulation of surface receptors, release of endocytosed nutrients, antigen 
processing and inactivation of pathogenic organisms are attributed to the normal 
function of lysosomes (for review see Mullins and Bonifacino 2001). At 
present, a dynamic model of lysosome function is suggested in which 
lysosomes constanly fuse with late endosomes and are then re-formed from the 
late endosome/lysosome hybrid organelles (Figure 2) (Luzio et al. 2000; Luzio   21
et al. 2001). A dynamic model is also supported by the identification of so-
called secretory lysosomes, which secrete their contents after fusion with the 
plasma membrane. They have been found predominantly in cells of 
hemopoietic lineage, such as T cells, platelets and osteoclasts, but also in 
melanocytes and renal tubular cells (Orlow 1995; Swank et al. 1998; 
Stinchcombe and Griffiths 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. A schematic picture of the endosomal/lysosomal pathway and of the targeting of 
newly synthesized lysosomal membrane proteins. They are sorted at the trans-Golgi network 
(TGN) and transported either via the plasma membrane by AP-2 mediated recognition or 
directly to the endosomal/lysosomal pathway by AP-1, AP-3 or AP-4 mediated route. 
 
3.2. Proteins of the lysosomal membrane 
An essential function of the lysosomal membrane is to prevent unwanted 
degradation of other cellular components by the acidic hydrolases. It also 
controls the entry of compounds to be degraded as well as the exit of digestion   22
products. In addition, maintenance of the acidic pH within the lumen is a major 
function attributed to the lysosomal membrane. The integral membrane proteins 
are responsible for transporting small molecules, e.g. amino acids and sugars 
resulted from the degradation, out from the lysosome. The major and human 
disease-associated lysosomal membrane proteins are illustrated in Figure 3 on 
page 21. 
 
3.2.1. Targeting of lysosomal membrane proteins 
The intracellular organelles along the endosomal-lysosomal pathway must 
maintain the specific set of membrane proteins in order to perform their 
functions. The lysosomal membrane proteins are generally targeted from the 
trans-Golgi network (TGN) to their destination either via the plasma membrane 
by AP2-mediated recognition of a tyrosine-based or di-leucine signal present in 
the cytosolic tail (or loop) of the protein or they can be delivered to lysosomes 
directly using an alternative sorting machinery (Figure 2) (Corvera et al. 1994; 
Ohno et al. 1995; Marks Michael S. 1997; Le Borgne and Hoflack 1998). Many 
lysosomal membrane proteins have been shown to interact with the AP3 
adaptor complex (Le Borgne et al. 1998). Other sorting motifs or structural 
requirements for the proper targeting exist and more are likely to be identified, 
since the classical motifs recognized so far are not present in all lysosomal 
membrane proteins (Cherqui et al. 2001). 
 
3.2.2. Major lysosomal membrane proteins 
About 50% of the protein in the lysosomal membrane comprise of heavily 
glycosylated, acidic, integral membrane proteins called lysosome-associated 
membrane proteins (LAMPs), lysosomal membrane glycoproteins (LGPs) and 
lysosomal integral membrane proteins (LIMPs).    23
LAMP-1 and LAMP-2 are highly homologous, structurally related proteins with 
one TM domain, a short cytoplasmic tail and a highly glycosylated intraluminal 
domain (Carlsson et al. 1988; Fukuda et al. 1988). The sugar residues constitute 
more than half of the total mass of the LAMP molecules (Fukuda 1991). The 
short cytosolic tail of LAMPs contains the tyrosine-based signal for lysosomal 
targeting. LAMP-1 and LAMP-2 genes are located on different chromosomes 
and the LAMP-2 gene encodes three transcripts giving rise to isoforms LAMP-
2a, LAMP-2b and LAMP-2c with different TM domains and cytoplasmic tails 
(Mattei et al. 1990; Sawada et al. 1993; Hatem et al. 1995). In addition to the 
prevailing localization in the lysosomal/late endosomal membranes, LAMPs are 
also found in small amounts in membranes of early endosomes and in the 
plasma membrane (Lippincott-Schwartz and Fambrough 1987; Furuno et al. 
1989; Griffiths et al. 1989; Fukuda 1991). The functions of LAMP-1 and 
LAMP-2 have long been elusive and only recently LAMP-2 was proposed to 
have a role in the selective uptake and degradation of cytosolic proteins (Cuervo 
and Dice 1996). Furthermore, an impaired recycling of 46 kDa mannose 6-
phosphate receptors and a partial mistargeting of some lysosomal enzymes were 
observed in cultured hepatocytes from LAMP-2-deficient mice, suggesting a 
possible role for LAMP-2 in lysosomal biogenesis and autophagy (Eskelinen et 
al. 2002). In LAMP-1 deficient mice the properties of lysosomes were similar to 
those of controls but LAMP-2 was shown to be upregulated, which suggests 
that LAMP-2 could compensate for the LAMP-1 deficiency (Andrejewski et al. 
1999). 
Although not as abundant as LAMPs, LIMP-1/CD63 and LIMP-2/LGP85 also 
represent major components of lysosomal membranes. They exhibit no 
homology to LAMPs or to each other. LIMP-1 was originally identified as an 
antigen on the surface of activated blood platelets but has later been shown to 
colocalize with other lysosomal membrane proteins (Modderman 1989;   24
Metzelaar et al. 1991). More specifically, LIMP-1 is predominantly localized on 
the internal membranes of endosomes and lysosomes (Escola et al. 1998). 
LIMP-1/CD63 has been proposed to have a potential role in eosinophil 
activation and also in the fusion of secretory granules with the plasma 
membrane (Cham et al. 1994; Skubitz et al. 1996; Cieutat et al. 1998; 
Mahmudi-Azer et al. 2002). LIMP-2/LGP85 has been implicated a role in the 
biogenesis and maintenance of endosomes/lysosomes. Overexpression of this 
protein resulted in enlarged early endosomes and late endosomes/lysosomes 
(Kuronita et al. 2002). The important role of LIMP-2/LGP85 in lysosomal 
biogenesis is further highlighted by the phenotype of LIMP-2 knockout mice, 
which develop a urogenital tract obstruction, deafness and peripheral 
neuropathy (Gamp et al. 2003). 
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Figure 3. A schematic picture of the major and human disease-associated lysosomal membrane 
proteins. 
 
 
3.2.3. Sialic acid transporter (sialin) 
The protein responsible for the transport of free sialic acid from lysosomes is  
defective in patients with free sialic acid storage disorders (Renlund et al. 
1986). This lysosomal sialic acid transporter was purified from rat liver and was 
shown to recognize structurally different types of acidic monosaccharides, 
including sialic acid, glucuronic acid and iduronic acid (Mancini et al. 1989; 
Mancini et al. 1992a; Havelaar et al. 1998; Havelaar et al. 1999). 
Characterization of the protein revealed remarkable biochemical and functional   26
similarities, including an overlap in substrate specificity and a similar proton 
cotransport mechanism, to the monocarboxylate transporters of the plasma 
membrane (Havelaar et al. 1998). This transporter also showed a wide substrate 
specificity for organic anions (Havelaar et al. 1999). This protein will be 
discussed in more detail in the results and discussion section of this thesis. 
 
3.2.4. Cystinosin  
Cystinosin is a 367 aa protein with seven predicted transmembrane (TM) 
domains and a 128 aa N-terminal region in the lysosomal lumen. The cytosolic 
C-terminal tail contains a lysosomal targeting signal (GYDQL), but an 
additional conformational motif (YFPQA) in the third cytoplasmic loop is 
required for the proper lysosomal targeting (Cherqui et al. 2001). The ability of 
cystinosin to transport cystine was shown by creating an experimental model in 
COS cells in which the overexpressed protein was redirected to the plasma 
membrane by deleting the C-terminal targeting signal (Kalatzis et al. 2001).  
The ability of the transfected cells to take up labeled cystine from the 
extracellular medium was then measured. The transport of cystine was shown to 
be driven by a proton transmembrane gradient. Defective function of this 
protein leads to intra-lysosomal accumulation of cystine and results in 
cystinosis, which will be discussed later in greater detail. 
 
3.2.5. CLN3 
CLN3 (battenin) is an ~43 kD glycoprotein consisting of 438 amino acid with 
6-8 predicted transmembrane domains (Janes et al. 1996). In the predicted 
topology model, the amino- and carboxyterminal ends face the cytosolic side of 
the membrane. In addition, a different topology model with only five TM 
domains, luminal amino- and cytosolic carboxy terminus, has recently been 
proposed for CLN3 (Mao et al. 2003). CLN3 has been shown to localize to   27
lysosomal compartment in non-neuronal cells (Jarvela et al. 1998) but some 
controversy exists, since some studies propose intracellular localization in the 
Golgi (Kremmidiotis et al. 1999), endoplasmic reticulum (Kida et al. 1999) as 
well as cell membranes and nucleus (Margraf et al. 1999). Interestingly, CLN3 
does not show obvious co-localization with a lysosomal marker in neuronal 
cells. Instead, it is present in the synaptosomal fraction of neurons and co-
localizes with presynaptic markers (Luiro et al. 2001). The function of CLN3 
remains unclear but involvement of the endocytic pathway has been implicated 
in studies with different deletion mutants of its yeast homologue (Pearce et al. 
1999; Chattopadhyay et al. 2003). The impairment of CLN3 results in Batten 
disease, discussed in more detail in the next chapter. 
 
3.2.6. NPC1 
The NPC1 protein is defective in patients with Niemann-Pick type C disease. It 
consists of 1278 amino acids and has 13 predicted transmembrane domains 
(Davies and Ioannou 2000). The amino-terminal part of NPC1 contains a region 
of 111 aa (NPC domain) that has close homology with other NPC1 orthologs. 
Within this region lie eight conserved cysteine residues and a leucine zipper 
domain with a proposed function in mediating protein dimerization (Carstea et 
al. 1997). NPC1 also has a sterol-sensing domain that is shared by the key 
regulators of cholesterol metabolism (Carstea et al. 1997). A di-leucine (LLNF) 
motif, implicated in lysosomal targeting and as an endocytic signal, is found in 
the carboxy-terminus of NPC1 (Corvera et al. 1994; Petris and Mercer 1999). 
Currently, however, the intracellular trafficking pathway of NPC1 from the 
Golgi is not clear and more studies are needed to determine the targeting signals 
and their interactions with the adaptor molecules mediating the different routes 
to the lysosomes. NPC1 controls the trafficking of cholesterol and also of other 
lipids, especially sphingolipids (Liscum 2000; Lusa et al. 2001; Zhang et al.   28
2001). The exact mechanism(s) and the intracellular pathway(s) of NPC1-
regulated cholesterol transport are still somewhat elusive. Recent data also 
suggest a possible function for NPC1 as a transmembrane pump and as a 
regulator of NPC2 transport (Davies et al. 2000; Blom et al. 2003).   
 
3.2.7. MLN1 
Mucolipin-1 (MLN1) is a 580 aa protein encoded by the MCOLN1 gene, in 
which mutations have been found in patients suffering from mucolipidosis type 
IV (MLIV) (Bargal et al. 2000; Bassi et al. 2000; Sun et al. 2000). MLN1 is an 
integral membrane protein predicted to have six TM domains with both the 
amino- and carboxytermini in the cytosol. There are no published reports on the 
subcellular localization of endogenous MLN1 in mammalian cells, but given 
the proposed defect of MLIV in late steps of endocytosis, it is presumed that the 
protein should mainly be expressed in lysosomal and late endosomal 
membranes. Indeed, when overexpressed, it has been observed in structures that 
colocalize with a lysosome-selective probe as well as in clusters near or on the 
plasma membrane (Bassi et al. 2000; LaPlante et al. 2002). The amino acid 
sequence of mucolipin-1 has a calcium and sodium channel pore region within a 
transient receptor potential (TRP) cation channel domain. It also contains a 
lysosomal targeting signal, a di-leucine motif in the C-terminus (Sun et al. 
2000). MLN1 showed sequence similarity to polycystin-2 encoded by the 
PKD2 gene involved in autosomal dominant polycystic kidney disease 
(ADPKD). MLN1 was shown to function as a novel Ca
2+-permeable channel 
that is transiently modulated by changes in the concentration of Ca
2+ (LaPlante 
et al. 2002). It could be involved in Ca
2+ transport across lysosomal membranes 
or in Ca
2+-dependent fusion between the lysosomal and the plasma membrane 
(Lemons and Thoene 1991).  Recently, a loss-of-function mutation was 
identified in the C. elegans mucolipin-1 homologue, cup-5, and it was shown to   29
result in decreased degradation of endocytosed protein and accumulation of 
large vesicles. Overexpression of this protein caused the opposite phenotype, 
suggesting a role for CUP-5 in the regulation of endocytosis (Fares and 
Greenwald 2001). 
 
3.2.8. Other proteins of the lysosomal membrane 
The evolutionally conserved vacuolar proton pump (V-type H
+-ATPase) is a 
complex of at least 13 subunits and resides in the lysosomal membrane (Forgac 
1999). It couples the hydrolysis of ATP to the translocation of protons and is 
responsible for the acidification of the lysosomal lumen. Mice deficient in an 
osteoclast-specific proton pump subunit (OC-116kDa) develop severe 
osteopetrosis as a result of defective acidification of the extracellular lysosomes 
of osteoclasts (Li et al. 1999).  
At least ten different amino acid transporters have been described in human 
cells and their specificities cover all but two amino acids, asparagine and 
glutamine (Lloyd 1996). These might be exported as dipeptides by a low-
affinity oligopeptide transporter recently described in rat liver and kidney 
lysosomes (Zhou et al. 2000). However, the only amino acid transporter cloned 
so far is the cystine transporter, cystinosin. Three monosaccharide transporters, 
including the one for sialic acid, have been described with specificities for all 
monosaccharides produced by the breakdown of glycoconjugates in mammalian 
lysosomes (Lloyd 1996). A possible nucleotide transporter, LAPTM4α, and two 
putative ATP-binding cassette (ABC) transporters, ABCA2 and ABCB9, have 
also been shown to localize in the lysosomal membrane  (Zhang et al. 2000; 
Vulevic et al. 2001; Hogue et al. 2002).  NRAMP2/DTM1 is a pH-dependant 
divalent metal/proton  symporter localized to the membrane of late endosomes 
and lysosomes and is proposed to function as an iron transporter in the 
transferrin cycle (Gunshin et al. 1997; Tabuchi et al. 2000).     30
Endolyn is a type I membrane protein present in endosomal and lysosomal 
compartments in mammalian cells (Croze et al. 1989). It has a heavily 
glycosylated luminal domain and a short, tyrosine-containing cytoplasmic tail 
(Croze et al. 1989; Ihrke et al. 2000). In addition, a strong N-glycan-dependent 
apical targeting signal directs endolyn to lysosomes via the apical surface of 
polarized epithelial cells (Ihrke et al. 2001). Endolyn shares sequence 
similarities with a family of mucins, proteins containing large amounts (> 40%) 
of proline, serine and threonine residues and of O-linked oligosaccharides, 
implicated in cell adhesion (Van Klinken et al. 1995). Interestingly, it also 
contains a conserved domain previously found in proteins of the growth factor 
and cytokine receptor families.  
As well as structural membrane proteins, some enzymes are also associated 
with the lysosomal membrane. The lysosomal acid phosphatase (LAP) is 
synthesized as a transmembrane precursor which, after arrival at late endosomes 
or lysosomes, is cleaved to the enzymatically active, soluble form (Peters and 
von Figura 1994). LAP is thus only transiently a lysosomal membrane protein. 
Another enzyme, Acetyl-CoA:α-glucosamidine N-transferase, is also a resident 
of the lysosomal membrane. It catalyses the transfer of an acetyl group from 
acetyl-CoA in the cytosol to terminal glucosamine residues of heparin sulphate 
in the lysosomal lumen (Bame and Rome 1985). This transferase supposedly 
spans the membrane or is tightly membrane-bound, but the precise structure has 
not been resolved nor the gene cloned (Bame and Rome 1986). Acetyl-CoA:α-
glucosamidine  N-transferase was recently shown to be associated with 
detergent-resistant microdomain (DRM) or raft fractions of lysosomal 
membranes (Taute et al. 2002). A genetic deficiency of this enzyme leads to 
Sanfilippo disease type C (MPSIIIC), a severe lysosomal storage disorder in 
which heparin sulphate and heparin accumulate in the lysosomes (Klein et al. 
1978).    31
Interestingly, it has recently been shown that nicastrin is a resident lysosomal 
membrane protein and that nicastrin, presenilin-1 (PS1), amyloid precursor 
protein (APP) and γ-secretase activity are co-localized in the lysosomal 
membrane (Bagshaw et al. 2003; Pasternak et al. 2003). These proteins are 
involved in the production of β-amyloid peptides which form amyloid plaques 
in the brain in Alzheimer’s disease (Selkoe 2000). 
 
 
4. Human diseases associated with defects of lysosomal 
membrane proteins 
 
DISEASE  DEFECTIVE 
PROTEIN 
PRESUMED 
FUNCTION 
CELLULAR 
PATHOLOGY 
Danon Disease  LAMP-2  Lysosomal biogenesis and 
chaperone-mediated 
autophagy  
Accumulation of 
cytoplasmic vacuoles 
containing autophagic 
material and glycogen 
Cystinosis Cystinosin  Cystine  transporter Lysosomal  accumulation 
of cystine 
Batten disease  CLN3  Involved in endocytic 
pathway 
Lysosomal accumulation 
of mitochondrial ATP 
synthase subunit c 
Niemann-Pick 
type C 
NPC1  Trafficking of cholesterol 
and lipids 
Lysosomal accumulation 
of cholesterol 
Mucolipidosis 
IV 
Mucolipin-1 
(MLN1) 
Ca
2+ channel  Lysosomal accumulation 
of sphingolipids, 
phospholipids and 
mucopolysaccharides 
SASD  Sialin  Sialic acid transporter Lysosomal  accumulation 
of free sialic acid 
 
Table 2. Human diseases associated with defects of lysosomal membrane proteins and the 
presumed function of these proteins.  
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4.1. Danon disease 
Danon disease (DD) (“lysosomal glycogen storage disease with normal acid 
maltase”) (OMIM 309060) is caused by mutations  in the gene coding for 
LAMP-2 (Nishino et al. 2000). It is characterized by cardiomyopathy, 
myopathy and variable mental retardation. A distinctive feature of DD is the 
accumulation of  cytoplasmic vacuoles containing autophagic material and 
glycogen in cardiac and skeletal muscle, a hallmark feature also observed in 
LAMP-2-deficient mice (Tanaka et al. 2000). The LAMP-2 deficient mouse is a 
valuable animal model of Danon disease and provides tools for analyzing the 
function(s) of LAMP-2 in more detail. So far, 14 patients with similar 
symptoms have been described (Danon et al. 1981; Riggs et al. 1983; Dworzak 
et al. 1994; Nishino et al. 2000). The inheritance is considered to be X-linked, 
since in most familial cases predominantly males are affected. Due to the fact 
that the function of LAMP-2 has only recently started to clarify, the exact 
disease mechanism is as yet unknown.  
LAMP-2 gene consists of nine exons of which exons 1-8 and a part of exon 9 
encode the luminal portion of the corresponding polypeptide, the 
transmembrane and the cytosolic domain being encoded by the rest of exon 
nine. In humans, two isoforms, LAMP-2a and LAMP-2b, are produced by 
alternative splicing of exon 9 (Konecki et al. 1995). At the mRNA level the 
LAMP-2b isoform is more abundantly expressed than LAMP-2a in heart, 
skeletal muscle and brain and it is suggested that the disease is mainly due to 
defects of the LAMP-2b isoform. Of the eight mutations found in ten patients 
with Danon disease, seven result in loss of the transmembrane and cytosolic 
domains of LAMP-2. LAMP-2 was shown to be absent from muscle sections of 
DD patients by immunohistochemistry.  
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4.2. Cystinosis 
Impaired function of cystinosin leads to cystinosis. This is a rare, autosomal 
recessive disorder characterized by intra-lysosomal accumulation of cystine as a 
result of defective transport out of these organelles (Gahl et al. 1982). Cystine is 
formed as a by-product of protein degradation and normally exits from the 
lysosomes to be reduced to cysteine in the cytosol. The phenotypic spectrum of 
cystinosis is wide and three allelic clinical forms can be distinguished (for 
review see Gahl et al. 2001). The infantile form (OMIM 219800) is the most 
severe and leads to renal failure at around 10-12 years. The widespread 
accumulation of cystine in most tissues can result in retinal blindness, diabetes 
mellitus, hypothyroidism and eventually neurologic deterioration. In juvenile 
cystinosis (OMIM 219900), the renal symptoms appear approximately at 12-15 
years of age, whereas adults with ocular cystinosis (OMIM 219750) do not 
manifest any renal deterioration. The treatment of cystinosis is based on 
administration of cysteamine which is able to enter the lysosomes and react 
with free cystine to form free cysteine and a disulphide of cysteamine and 
cysteine (Thoene et al. 1976). This mixed disulphide is then exported from the 
lysosomes by a membrane carrier for cationic amino acids (Pisoni and Velilla 
1995). In cystinosin-deficient mice the intralysosomal accumulation of cystine 
and the distribution of the cystine crystals are comparable to those in cystinosis 
patients. These mice, however, did not show signs of the renal failure or 
proximal tubulopathy seen in the affected human patients (Cherqui et al. 2002). 
Cystinosis is caused by a variety of mutations in the CTNS gene (Town et al. 
1998). The most common mutation is a 57 kb deletion (originally reported as a 
65 kb deletion) which encompasses the 5’ end of the gene and results in the 
absence of mRNA (Town et al. 1998; Anikster et al. 1999). This deletion and 
one nonsense mutation (W138X) in homozygous form, as well as in 
combination with other mutations leading to truncated polypeptide, always   34
produces the severe infantile phenotype (Attard et al. 1999). All patients with 
the 57 kb deletion have a European ancestry and a German founder has been 
implicated (Shotelersuk et al. 1998). Interestingly, a novel gene, CARKL, was 
found within this common cystinosis-causing deletion. By homology searches, 
the predicted polypeptide encoded by CARKL was shown to be similar to 
carbohydrate kinases from different species. It is hypothesized that CARKL, or 
its absence, might account for some of the phenotypic heterogeneity seen in 
cystinosis (Touchman et al. 2000). 
 
4.3. Batten disease 
Batten disease (juvenile neuronal ceroid lipofuscinosis, JNCL)(OMIM 204200 ) 
is the most common neurodegenerative disease of childhood (Santavuori et al. 
2000). It belongs to an entity of at least eight different progressive 
neurodegenerative diseases called neuronal ceroid lipofuscinosis (NCLs) 
(Goebel 1995; Santavuori et al. 2000). The clinical features of Batten disease 
consist of visual failure, epilepsy, psychomotor retardation and premature death. 
Batten disease is characterized by intracellular accumulation of autofluorescent 
material, mainly mitochondrial ATP synthase subunit c, within lysosomes 
(Palmer et al. 1992). Intracellular storage similar to Batten disease patients and 
also neuropathological abnormalities are seen in two different mouse models 
generated for Batten disease. In the homozygous Cln3
∆ex7/8 knock-in mice, the 
accumulation in peripheral cells and CNS neurons was evident already in 
embryos and they were more symptomatic than the Cln3-deficient mice in 
general (Mitchison et al. 1999; Cotman et al. 2002).  
Batten disease is autosomal recessively inherited and caused by mutations in the 
CLN3 gene (Consortium 1995). Most of the patients carry a 1.02 kb genomic 
deletion which removes exons seven and eight from the coding region but more   35
than 20 different mutations have been characterized (Mole and Gardiner 1999). 
Some genotype-phenotype correlation exists, since the phenotype resulting 
from the homozygous major deletion is always the classical, severe JNCL, 
while the compound heterozygotes have a milder phenotype (Consortium 1995; 
Jarvela et al. 1997; Munroe et al. 1997; Wisniewski et al. 1998; Lauronen et al. 
1999).  
  
4.4. Niemann-Pick type C disease (NPC) 
NPC is an autosomal recessively inherited neurodegenerative disorder which 
belongs to the lysosomal storage disorders. The disease leads to lysosomal 
accumulation of low density lipoprotein (LDL)-derived cholesterol, resulting in 
disturbances on cholesterol homeostasis (Vanier and Suzuki 1998; Patterson et 
al. 2001). The clinical manifestations are heterologous and the age of onset 
varies from infancy to adulthood. The most severe, rapidly progressing form of 
the disease presents in infancy and results in death before the age of two years. 
The “classic” NPC is characterized by hepatosplenomegaly, progressive ataxia, 
dystonia, vertical supranuclear ophthalmoplegia and dementia. The onset of the 
classic phenotype is in early childhood and death ensues in the second or third 
decade. In the late onset form the first symptoms appear in adolescence or 
adulthood and cognitive and psychiatric disturbances predominate. 
One feline, one canine and two murine models for NPC are known (Shio et al. 
1982; Weintraub et al. 1985; Tanaka et al. 1988; Lowenthal et al. 1990; 
Kuwamura et al. 1993). Although these animal models exhibit features of NPC 
closely resembling those in NPC patients, the basis for the progressive 
neurodegeneration and abnormal brain function has not been resolved. 
In NPC disease two complementation groups have been identified (Steinberg et 
al. 1994; Vanier et al. 1996). Most (90-95%) cases of NPC result from   36
mutations in the NPC1 gene (Carstea et al. 1997). Recently, another gene, 
HE1/NPC2, was identified as the disease-causing gene in patients with NPC2 
(Naureckiene et al. 2000).   
 
4.5. Mucolipidosis type IV 
Mucolipidosis type IV (MLIV) is an autosomal recessively inherited, 
neurodegenerative storage disorder characterized by lysosomal accumulation of 
sphingolipids, phospholipids and acid mucopolysaccharides (Berman et al. 
1974; Riedel et al. 1985; Goldin et al. 1999; Slaugenhaupt et al. 1999). Unlike 
in most lysosomal storage diseases, the lysosomal hydrolases participating in 
the catabolism of the stored material are normal. The defect was observed to lie 
in an abnormal endocytosis of membrane components rather than in defective 
degradation (Chen et al. 1998). Approximately 100 patients have been 
described so far and more than 80% of the MLIV patients are Ashkenazi Jews. 
Corneal clouding and a progressive retinopathy are characteristic of MLIV and 
the disease leads to severe visual impairment (Riedel et al. 1985). The majority 
of the patients also have constitutive achlorhydria and secondary elevation of 
the serum gastrin level (Schiffmann et al. 1998). Most patients never learn to 
speak or walk independently and development ceases at the 1-2 year level. 
Despite the early age of onset, most patients show hardly any deterioration in 
the clinical picture in the first decades of life (Bargal and Bach 1997).  
The gene causing MLIV resides on chromosome 19 and was recently cloned 
(Slaugenhaupt et al. 1999; Bargal et al. 2000; Bassi et al. 2000; Sun et al. 2000). 
This gene, MCOLN1, consists of 14 exons and spans approximately 14 kb of 
genomic DNA. Among the Ashkenazi population, two founder mutations were 
identified, of which an intronic splice site mutation accounts for 72% and a   37
deletion of exons 1-7 for 23% of the mutated alleles. To date, 14 different 
mutations have been reported in MCOLN1 (Slaugenhaupt 2002). 
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AIMS OF THE PRESENT STUDY 
Prior to this study, the biochemical defect in SD and ISSD had been 
characterized and the precise genetic position of the gene was known. However, 
the causative gene remained unidentified. This study was undertaken to 
identify, clone and characterize the gene and the gene product defective in SD 
and ISSD in order to understand the disease pathogenesis. 
 
The specific aims were: 
 
1.  To identify the gene which causes free sialic acid storage diseases when 
mutated (I) 
 
2.  To identify and characterize mutations in this gene in patients affected 
with SASD (II) 
 
3.  To initiate the characterization of the protein and to study the cellular 
consequences of these mutations (III) 
 
4.  To study the expression of this gene and protein in the CNS in order to 
provide some understanding about the CNS manifestations of SD and 
ISSD (IV).  
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METHODS 
 
The methods used in the original articles included in this thesis are summarized 
in the following table. The number of the original publication in which the 
method has been used is indicated. 
 
 
Method                                                                                         Publication 
EST database searching                                                                  I 
cDNA library screening                                                                  I 
Computer sequence analysis (ClustalW, BLAST2, TopPred2)      I, II 
Northern hybridization                                                                    I, II 
RNA extraction                                                                               II, IV 
DNA sequencing                                                                             I-IV 
Allele-specific PCR                                                                         I, II 
Recombinant DNA techniques (cloning)                                        III, IV 
Site-directed mutagenesis                                                               III 
Cell culture techniques                                                                    III, IV 
Transient DNA transfection                                                            III, IV 
Virus infection                                                                                 III 
Generation of polyclonal antibodies                                               III, IV 
SDS-PAGE, immunoblotting, ECL  
(enhanced chemiluminescence)      
III, IV 
Immunofluorescence microscopy                                                   III, IV 
In vitro translation                                                                           III 
Temperature-induced transport block                                             III 
Metabolic labelling of cells and immunoprecipitation                   III 
Cell fractionation/Lysosome isolation                                            III 
Immunohistochemistry                                                                   IV 
In situ hybridization                                                                        IV 
Quantitative real-time PCR                                                             IV 
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RESULTS AND DISCUSSION 
 
1. Cloning of the SLC17A5 gene (I) 
1.1. Identification of ESTs in the disease locus 
The disease locus for Salla disease and for ISSD had previously been localized 
to the refined area on chromosome 6q14-q15 by linkage analysis and a physical 
map had been  constructed over the disease locus, flanked by markers D6S280 
and D6S1622 (Haataja et al. 1994b; Schleutker et al. 1995a; Leppanen et al. 
1996). Overlapping PAC clones 141B1, 202M22 and 252H1 covered this 200 
kb critical region. The Human Genemap 1998 provided by the international RH 
mapping consortium (Deloukas et al. 1998) was screened for ESTs in the 
immediate vicinity of central marker D6S1596. Several overlapping clones were 
identified from the genebank EST division (Boguski et al. 1993), which showed 
considerable similarity to the C. elegans hypothetical protein C38C10.2. This C. 
elegans protein was similar to mammalian Na
+/phosphate symporters and had 
been classified within the ACS family of anion/cation symporters. The ACS 
family contains eukaryotic inorganic anion transporters, such as Na
+/phosphate 
co-transporters, and also a bacterial glucuronic acid (hexuronate) transporter 
from E.coli (EXUT) (Pao et al. 1998). These EST’s were therefore considered 
good candidates for the sialic acid transporter gene. Three clones 667681, 
265499 and 209208 were ordered from the Image consortium for subsequent 
studies (Lennon et al. 1996). 
 
1.2. Finding a candidate cDNA for SASD 
The EST clones hybridized to PAC202M22 covering the critical disease region 
and were thus considered to be part of a functional and positional candidate   41
cDNA. Sequencing these ESTs showed that they represented only the 3’end of 
the cDNA, and therefore these ESTs were used as probes to screen a human 
fetal liver cDNA library to isolate the full-length cDNA. Several overlapping 
positive clones were obtained, PCR amplified and used as probes to screen 
more cDNA libraries (placenta and brain). This, together with rapid 
amplification of cDNA ends (RACE), resulted in obtaining a 2.5 kb sequence 
which included an open reading frame (ORF) of 1485 bp, predicting a 495 
amino acid protein sequence. A stop-codon was found upstream of the first 
ATG, suggesting that the translation-initiating methionine had been identified. 
Northern-blot analysis of human tissues showed ubiquitous expression of a 
major transcript of approximately 4.5 kb and an additional transcript of 
approximately 3.5 kb. 
 
1.3. Homology searches 
Sequence homology searches using the BLAST program (Altschul et al. 1997) 
revealed a significant homology with several members of the anion-cation 
symporter (ACS) family of transporters. This family contains several 
eukaryotic, inorganic anion transporters (Na
+/phosphate cotransporters) as well 
as prokaryotic organic anion transporters, including H
+/acid sugar symporters 
for hexuronate and glucarate. ACS members transport their substrates in 
symport with either Na
+ or H
+ and they belong to the broad group of the major 
facilitator superfamily (MFS) of transporters (Pao et al. 1998). MFS 
transporters are defined as polytopic integral membrane proteins capable, as a 
single polypeptide, of transporting small solutes in response to chemiosmotic 
ion gradients and containing twelve to fourteen transmembrane domains. This 
gene was originally designated as the AST (for anion and sugar transporter) 
gene but is currently called the SLC17A5 gene.    42
 
 
Figure 4. A schematic picture of the predicted topology of sialin. It spans the membrane 12 
times and both the amino- and carboxytermini face the cytosol. The potential glycosylation sites 
are marked with asterisks. 
 
The polypeptide encoded by the SLC17A5 gene consists of 495 amino acids and 
is predicted to contain twelve transmembrane domains, like most MFS 
members (Figure 4). This protein was designated as sialin because of its relation 
to sialic acid storage diseases. According to the positive-inside rule (von Heijne 
1992), both the amino- and the carboxyterminal regions of sialin were predicted 
on the cytosolic side of the membrane. The polypeptide contains six putative N-
glycosylation sites and a consensus sequence of the ACS family is found in the 
fourth TM spanning region. Sialin does not contain an N-terminal signal 
sequence or any known targeting signal similarly to other mammalian ACS 
family members. The strong homology of sialin with human Na+-phosphate 
symporters (BNPI and NPT1) and with a H+-hexuronate symporter (EXUT) 
from E.coli extends over the whole ORF (Hugouvieux-Cotte-Pattat and Robert-
Baudouy 1987; Chong et al. 1993; Ni et al. 1996; Blattner et al. 1997). Sialin 
shows 37%, 34% and 16% sequence identity with BNPI, NPTI and EXUT, 
respectively.    43
1.4. Identifying mutations in the SLC17A5 gene 
To test whether SASD patients have mutations in SLC17A5, the cDNAs of five 
Finnish unrelated Salla disease and six ISSD patients were RT-PCR amplified 
and screened for mutations. All SD patients had a homozygous missense 
mutation 115C->T changing a conserved arginine residue to a cysteine residue 
(R39C) in the predicted protein sequence. The obligate carriers were 
heterozygous for this mutation. This mutation was confirmed in these patients 
and in an additional family with three healthy and three affected siblings on 
genomic DNA by allele-specific PCR (Wu et al. 1989). All the patients had 
only the mutation-specific PCR product, whereas none of the 100 Finnish 
controls had it (Figure 5). The R39C thus appeared to be a founder mutation in 
the Finnish population, causing the high incidence of SD in Finland (Peltonen 
1997). 
 
Figure 5.  Allele-specific PCR shows the segregation of the R39C mutation in a Finnish family 
from the Salla area. All the affected siblings have only the mutation-specific PCR product, 
whereas the parents and healthy siblings show both wild-type and mutated alleles. Black 
symbol: SD, grey symbol: carrier, C: control. Modified from (Verheijen et al. 1999). 
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The introduction of a cysteine residue at a conserved site may affect the primary 
folding of the protein and destroy its tertiary structure. Furthermore, the change 
from a positively charged amino acid (arginine) to an uncharged amino acid 
(cysteine) close to TM domain might affect the TM region itself. 
Six different mutations were found in six ISSD patients of various ethnic 
origins. These included one homozygous insertion (978-979ins500bp) and 
deletion (802-816del15bp), two deletions (533delC/1112-1259del148bp) and 
two missense mutations (548A->G/1001C->T) in compound heterozygous 
form. One patient was found to carry the 15 bp deletion (802-816del15bp) in 
one allele but the mutation in the other allele was not detected. All SLC17A5 
mutations are listed in Table 3 on page 43.  
These results, combined with the knowledge of the functional defect, provided 
the evidence for SLC17A5 being the gene underlying free sialic acid storage 
diseases. 
 
 
2. Characterization of the SLC17A5 gene and the spectrum of 
disease-causing mutations (II) 
2.1. Genomic organization of the gene 
The human database for genomic clones was searched using the BLASTN 
algorithm (Altschul et al. 1990) with the SLC17A5 cDNA as the query 
sequence. This search yielded one Homo sapiens clone (HSJ397H23) that 
contained 22 unordered pieces of genomic DNA covering the SLC17A5 cDNA. 
Ten complete exons were included in this sequence, which covered most of the 
ORF of SLC17A5. To determine the missing 5’ exon, a genomic clone (PAC 
202M22) covering the gene was sequenced. All the exons were amplified from   45
genomic DNA using intronic primers flanking the intron-exon boundaries. By 
this approach, all 11 exons covering the whole ORF were determined. Due to 
the missing 5’ sequence, the exact length of the first exon could not be resolved. 
An average protein-coding gene contains approximately 9 exons, the mean 
value for a coding sequence is 1340 bp and 27 kb for genomic extent (Lander et 
al. 2001). SLC17A5 has 11 exons, a coding sequence of 1485 bp and it spans a 
60 kb region in genomic DNA. Except for its genomic size, it thus falls into the 
category of an average protein-coding gene. A schematic picture of the 
SLC17A5 gene and the distribution of mutations are shown in Figure 6. 
Figure 6. A schematic illustration of the SLC17A5 gene and the distribution of mutations in 
patients included in this study. Mutations in ISSD patients are marked with a star.  
     
2.2. The spectrum of mutations 
2.2.1. Founder mutation SallaFIN (R39C)  
Allele-specific PCR was used to screen for the 115C->T mutation in 80 Finnish 
SD patients. This mutation, designated SallaFIN, was found in 95% of all disease 
alleles. Most patients (73) were homozygous for SallaFIN and seven were 
compound heterozygotes harbouring another mutation in the other allele. The 
presence of a founder mutation was not surprising, since earlier haplotype   46
analysis had revealed a common haplotype in 91% of the disease chromosomes 
between the markers flanking the ~60 kb disease locus (Schleutker et al. 
1995b). This phenomenon is a characteristic feature of the diseases belonging to 
the Finnish disease heritage (Peltonen 1997; Peltonen et al. 1999). The carrier 
frequency of SallaFIN was shown to be four times higher in the northeastern 
Salla-Kuusamo area (1.87%) than the nationwide carrier frequency (0.44%). 
This correlates well with earlier estimates based on the prevalence of the 
disease (Aula et al. 1986). Based on the long genetic interval (~10 cM) 
revealing significant linkage disequilibrium in the SD chromosomes, it has been 
estimated that the mutation was introduced into the Salla-Kuusamo area some 
20-30 generations (i.e. 500-750 years) ago (Schleutker et al. 1995a; Varilo 
1999). 
Twelve of 15 Swedish SD patients were homozygous for the SallaFIN mutation, 
two were heterozygous and one patient did not have this mutation in either 
allele. This finding is not surprising, considering the admixture of Finnish and 
Swedish populations during the centuries through which they shared a common 
history. In contrast, finding the SallaFIN mutation in a heterozygous form in five 
non-Scandinavian patients was quite unexpected. These patients had no known 
relationship to Finland, were unrelated and of various ethnic origins (British, 
Dutch, Italian and German). This raises the possibility that the SallaFIN mutation 
arrived in Finland with immigrants from Europe. 
 
2.2.2. Mutations in Finnish compound heterozygote SD patients 
The mutations in the other Finnish alleles were identified from three patients by 
cDNA sequencing. Two patients shared a 294 bp deletion (526-819del) 
encompassing exons 4 to 6 which is predicted to result in an in-frame deletion 
of 98 amino acids. The deleted region includes the same five amino acids 
(SSLRN) deleted in six severely affected ISSD patients (see below). In one   47
patient, a missense mutation, 406G->A, was identified, leading to a lysine to 
glutamic acid change in a cytosolic loop between the second and third TM 
domains. In three patients, the second mutation was identified by genomic DNA 
sequencing. They shared a two base pair deletion (1007-1008del) in exon 8 
resulting in a frameshift and, accordingly, the formation of 13 novel amino 
acids followed by a premature stop codon. The mutation of the other allele 
remained unidentified in two compound-heterozygote cases. All the mutations 
are presented in Table 3. 
 
 
2.2.3. Mutations in non-Finnish compound heterozygote SD patients  
Two novel mutations in the two Swedish compound-heterozygote SD patients 
were found by genomic DNA sequencing. One patient had a nonsense mutation 
(309G->A) in exon 3 predictably leading to a short (102 aa) translation product. 
The other was found also to carry a nonsense mutation (719G->A) in exon 6. In 
the Swedish SD patient without the SallaFIN mutation, an intronic mutation (95-
1G->C) was detected in heterozygous form. This presumably results in exon 
skipping, since cDNA sequencing revealed a deletion covering the whole exon 
2. The other mutated allele carried the deletion (1007-1008del) found in three 
Finnish compound heterozygotes (see above). 
In the five non-Scandinavian SD patients carrying the SallaFIN mutation, three 
of the other disease alleles were identified by genomic sequencing. The German 
patient had a genomic deletion encompassing exons 3 and 4, and the English 
sisters had a 2-bp deletion (1138-1139del) in exon 9. The second allele in two 
foreign patients remained unknown. In conclusion, five novel mutations were 
identified in the non-Finnish compound-heterozygote SD patients. 
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Phenotype  Mutations  
Allele 1  /   Allele 2 
Amino acid 
consequences 
Number/origin 
 of patients 
Classical  
Salla 
115C->T / 115C->T  Arg39Cys  73 Finnish,  
12 Swedish 
Intermediate, 
Severe SD 
115C->T / 
526-819del 
Arg39Cys / 
Deletion of exons 4-6 
2 Finnish 
  115C->T / 406A->G  Arg39Cys / Lys136Glu  1 Finnish 
  115C->T /  
1007-1008del 
Arg39Cys /  
premature stop 
4 Finnish 
  95-291del (cDNA) / 
1007-1008del 
Deletion of exon 2 / 
premature stop 
1 Swedish 
  115C->T / 309G->A  Arg39Cys / Trp103X  1 Swedish 
  115C->T / 719G->A  Arg39Cys / Trp240X  1 Swedish 
  115C->T /  
1138-1139del 
Arg39Cys /  
premature stop 
2 English 
  115C->T /  
292-611del 
Arg39Cys /  
deletion of exons 3 & 4 
1 German 
  115C->T / nd  Arg39Cys / ?  1 Finnish,  
1 Italian,  
1 Dutch 
ISSD  802-816del /            
802-816del 
In-frame deletion of  
5 amino acids 
1 Non-Scand. 
  802-816del / 1112G->T  In-frame deletion of 5aa 
/ Gly371Val 
1 Non-Scand. 
  802-816del /  
1355-1356insAA 
In-frame deletion of 5aa 
/ frameshift, 
readthrough of stop 
1 Non-Scand. 
  802-816del / nd  In-frame deletion of  
5 amino acids / ?  
3 Non-Scand. 
  526delG / 918T->G  Premature stop / 
Tyr306X 
1 Non-Scand. 
  533delC /  
1112-1259del 
Premature stop / 
deletion of exon 9 
1 Non-Scand. 
  548A->G / 1001C->G  His183Arg /Pro334Arg  1 Non-Scand. 
 978-979ins500bp  / 
978-979ins500bp  
Premature stop  1 Non-Scand. 
(Verheijen et al. 1999; Aula et al. 2000) 
 
Table 3. Mutations in the SLC17A5 gene in patients with SASD detected in the present study. 
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2.2.4. Mutations in ISSD patients 
None of the patients with ISSD had the SallaFIN mutation. Starting with cDNA 
and proceeding to genomic DNA sequencing altogether 10 different mutations 
were found in these patients (Table 2). These included missense and nonsense 
mutations, deletions, and insertions. Interestingly, the same 15-bp deletion 
(802-816del) was found in five unrelated patients of Canadian, English and 
French origin. One patient was a child of consanguineous parents and was 
homozygous for this mutation, while all the others were heterozygotes. This 
mutation leads to an in-frame deletion of five amino acids (SSLRN) in the third 
cytosolic loop of sialin. This same deletion has recently been found in 
compound heterozygote form in one American ISSD patient and in two patients 
(one American and one Italian) presenting the intermediate phenotype 
(Biancheri et al. 2002; Kleta et al. 2003). Finding the same mutation in many 
unrelated patients suggests a hidden, ancient relationship between these cases. 
The other mutations in these heterozygotes have been identified in two cases; 
one has a 2-bp insertion (1355-1356ins) leading to frameshift, formation of 
novel amino acids and a read through of the stop codon and the other was found 
to carry a missense mutation (1112G->T) changing a conserved glycine residue 
into a valine residue. One French patient was found to be a compound 
heterozygote having a 1-bp deletion (526del) in one allele and a nonsense 
mutation (918T->G) in the other. An Italian patient had a homozygous 500-bp 
insertion (978ins) leading to a truncated polypeptide, and two different 
missense mutations (548A->G and 1001C->G) were detected in a Yugoslavian 
patient. All in all, ten different mutations were identified in ten ISSD patients. 
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2.3. Genotype-phenotype correlation 
The phenotypic variation seen in Salla disease appears to some degree to 
correlate with the presence of the R39C mutation. SD patients who have the 
classical, slowly progressing Salla disease phenotype are all homozygous for 
the SallaFIN mutation. They present the typical symptoms of SD; early onset 
psychomotor retardation and ataxia, hypotonia and elevated excretion of free 
sialic acid in their urine (up to 30 times the normal values) (Renlund 1984; 
Varho et al. 2002). With one exception, the compound heterozygote patients are 
more severely affected than the R39C homozygotes. Furthermore, the level of 
free sialic acid in urine is usually higher in the compound heterozygotes than in 
the homozygotes. Interestingly, the non-Finnish patients having the SallaFIN 
mutation are also phenotypically milder than those who have completely 
different mutations. Many compound heterozygote patients have been classified 
as having the intermediate phenotype between the classical SD and ISSD 
phenotypes (Schleutker et al. 1995a). In patients with the most severe form of 
the disease, ISSD, neither of the mutated alleles carries the SallaFIN mutation. 
Thus, it seems that more of the protein’s normal function is retained with the 
R39C mutation in the sialin polypeptide as compared to other mutations found 
in compound heterozygote patients. If sialin functions as a dimer or multimer, 
neither the primary folding nor the potential multimerization seem to be greatly 
altered by the R39C mutation. The secondary structure of sialin is most 
probably more disturbed by the other mutations resulting in defective 
dimer/multimer formation or membrane targeting of the molecule. 
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3. Characterization of sialin (III) 
In order to characterize the intracellular localization and processing of sialin, 
the coding region of the SLC17A5 cDNA was amplified by RT-PCR from 
human lymphoblastoid total RNA and cloned into various expression vectors. 
Site-directed mutagenesis was used to generate two mutations into the wild-type 
SLC17A5 cDNA: the SallaFIN mutation (115C->T) and a deletion of five amino 
acids (802-816del) found in ISSD patients. A polyclonal antibody (7993) 
against a peptide corresponding to amino acids 251-265 in the third cytosolic 
loop of sialin was generated and used in all the expression studies. 
 
3.1. In vitro translation and biosynthesis of sialin 
In the in vitro translation, no effect on the production of the polypeptide was 
observed between the wild-type and mutant constructs. The observed size of the 
polypeptide (46 kDa), however, was smaller than the calculated molecular 
weight of sialin (54.6 kDa). This can be explained by an aberrant mobility of 
the nascent transmembrane protein in SDS-PAGE or modification steps later in 
the maturation process. One major polypeptide of approximately 52 kDa, absent 
from non-labeled cells, was observed in a pulse chase experiment in COS-1 
cells. Apparently no proteolytic processing occurs since the size of this 
polypeptide remained unchanged during all the chase periods. Furthermore, no 
difference in stability between the wild-type and mutant proteins could be 
noticed, suggesting that the SallaFIN and ISSD polypeptides are not severely 
misfolded and consequently degraded (Figure 7). 
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Figure 7. Pulse chase analysis of wild-type and mutant sialin polypeptides in COS-1 cells. 
Modified from (Aula et al. 2002). 
 
3.2. Confirming the lysosomal localization of sialin by cell 
fractionation 
Subcellular fractionation of Semliki Forest virus (SFV)-infected BHK cells was 
performed to confirm the lysosomal localization of sialin. The localization of 
endogenous sialin was analyzed from non-infected BHK cells. Consistent with 
the fractionation of lysosomal membrane proteins, sialin immunoreactivity was 
observed in the 1.000g post-nuclear supernatant (PNS) and in the 10.000g pellet 
(P1). After further enrichment of lysosomal proteins by a Percoll gradient, sialin 
was detected in the lysosomal fraction determined by immunoreactivity with a 
lysosomal marker. When fractions from SFV- and non-infected cells were 
compared, enrichment of sialin in the former could be seen. Thus, the 
presumptive lysosomal localization of sialin in these cells was ascertained. 
 
3.3. Intracellular localization and trafficking of wild-type sialin and 
mutant polypeptides 
The subcellular localization of sialin was analyzed in transiently transfected 
COS-1, BHK, and HeLa cells using the 7993 peptide antibody, organellar 
markers and confocal immunofluorescence microscopy. In all the cell lines, a 
punctuate peripheral staining, entirely co-localizing with a lysosomal membrane   53
marker (LAMP-1), was observed. When cells were transfected with the cDNA 
containing the SallaFIN mutation, the distribution of the protein was shifted to 
the Golgi compartment, while a fraction of the polypeptide still localized to the 
lysosomes. The majority of the ISSD polypeptides containing the 5 aa deletion 
was predominantly seen in the Golgi and only a minority could be observed in 
the lysosomes. The intracellular trafficking of sialin polypeptides was further 
studied, using a temperature-induced transport block. It is known that at 15°C 
the newly synthesized proteins accumulate in the intermediate compartment 
between ER and Golgi, ERGIC (Saraste and Kuismanen 1984). With the shift to 
the permissive temperature of the cells, the proteins continue their journey to 
their intracellular destination, allowing the routing to be monitored. After 
inducing the 15˚C temperature block to the transfected cells, the proteins were 
chased and fixed at different time points. The wild-type sialin could already be 
seen in the lysosomes after a one-hour chase, co-localizing with the LAMP-1 
marker, whereas the mutant proteins were both retained in the Golgi. Even two 
hours after removal of the temperature block, the mutant proteins were still in 
the Golgi compartment and had not reached the lysosomes. At this time point, 
however, a lysosomal distribution for a fraction of the SallaFIN polypeptides 
could also be observed. After four hours the majority of the ISSD polypeptides 
still remained in the Golgi while the SallaFIN polypeptides were also detected in 
lysosomes (Figure 8).   54
 
Figure 8: Distribution of the wild-type (A), SallaFIN (B) and ISSD (C) polypeptides in 
transiently transfected HeLa cells observed with confocal immunofluorescence microscopy 
after temperature-induced transport block. At one hour time point the wild-type protein has 
reached the lysosomes. After a four hour chase the SallaFIN polypeptides can be seen in the 
Golgi and the lysosomes, whereas the ISSD mutant is retained in the Golgi. Yellow indicates a 
co-localization of the sialin polypeptides (red) with the lysosomal marker (green).   
 
 
In agreement with the phenotypic differences in SD and ISSD patients, the 
trafficking of the ISSD deletion mutant into lysosomes was observed to be even 
slower than that of the SallaFIN mutant. Both of these polypeptides were able to 
pass the ER quality control suggesting that they are sufficiently correctly 
folded. However, the sorting machinery in the Golgi apparently does not fully 
recognize them as lysosomal proteins. Differing efficiency of the lysosomal 
targeting could explain some of the molecular mechanisms behind the 
phenotypic differences seen in SD and ISSD. In SD patients the mutant protein 
might still have a residual function in the lysosomes. In contrast, if most of the 
protein in ISSD patients never reaches the functional site, the lysosomes, the 
transport of sialic acid out from these organelles is likely to be negligible, 
leading to a more severe phenotype. The five amino acid deletion might also 
cause a structural derangement, rendering the protein totally inactive.    55
4. Expression of sialin in the mouse CNS and in primary 
neuronal cultures (IV) 
4. 1. Sialin is more abundantly expressed in neurons than in glia 
Both transcript and polypeptide levels were analyzed to monitor the expression 
of endogenous sialin in cultured mouse primary hippocampal and cortical 
neurons (5div) and glial cells by quantitative PCR (TaqMan) and by Western 
analysis using the peptide antibody 7993. A marked difference was observed in 
the distribution of expression, as immunoreactivity of sialin was strong in 
hippocampal and cortical neurons whereas only a faint band was detected in 
glial cells. A similar finding was established by a quantitative PCR analysis, in 
which the steady state level of the SLC17A5 transcript in glia was significantly 
lower than that in neurons (Figure 9). The cell type specific quantitative 
difference might thus result from the transcriptional regulation.  
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Western analysis shows that sialin is more abundant in neurons than in glia. The 
quantitative PCR analysis supports this finding: the steady state level of SLC17A5 transcript is 
lower in glia than in neurons. HC (hippocampus), C (cortex), G (glia).  
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4.2. Developmental expression pattern of SLC17A5 transcript and 
sialin in mouse brain  
Developmental expression pattern of SLC17A5 transcripts and the spatial-
temporal distribution of sialin polypeptide was studied in embryonic and 
postnatal mouse brains by nonradioactive in situ hybridization and 
immunohistochemistry using a sialin specific antibody (K4). This antibody was 
raised against a peptide corresponding to amino acids 263-277 in the predicted 
mouse sialin polypeptide. At the developmental stage E15.5 both the transcript 
and the protein were observed in the postmitotic neuroblasts of the cortical 
plate. The most intense signal was observed in the prospective neocortex and 
the hippocampus where the SLC17A5 transcript as well as the protein were 
localized in the ventricular progenitor cells. These cells have been shown to be 
a source of neurons and some glial cells (Del Rio et al. 2000). Also other brain 
areas, such as the thalamus, were immunopositive for sialin. The expression 
was seen throughout the cortical layers, except the marginal zone, at P1. In the 
cerebellum, however, the expression was detected at P5 when the signal was 
localized to the developing Purkinje cell layer. In the adult brain the expression 
of sialin covered several different brain regions including the cerebral and 
cerebellar cortices. Intensive sialin expression was also detected in the mitral 
neurons of olfactory bulb. These findings, combined with the data from 
analyses of CNS primary cell cultures, strongly suggest a neuronal origin of 
sialin. An oligodendroglial expression of sialin cannot be ruled out, however, 
since an intense immunopositivity for sialin could also be seen in the white 
matter following both spatially and temporally the staining pattern of myelin 
basic protein. This staining could reflect an axonal distribution of sialin (see 
later 4.3).    57
4.2.3. Sialin expression in SD brain 
The spatial expression pattern in adult mouse brain correlated well with the 
brain regions most affected in SD patients, namely cerebellum, cortex and 
corpus callosum. The distribution of sialin was also studied in brain sections (a 
courtesy of Professor Hannu Kalimo, University of Turku) from Salla disease 
patient by immunohistochemistry.  Sialin immunopositivity was observed in the 
cortical neurons which, compared to normal control, had a shrunken 
appearance. The cortical neurons in the control brain showed a granular staining 
pattern also in the neuronal extensions, whereas the SD neurons lacked the 
neuritic staining. In the SD patient the Purkinje cells of the cerebellum were 
clearly reduced in number but were immunopositive for sialin yet lacking the 
neuritic staining. In the control sections these cells showed staining in the cell 
soma and in neuritic extensions.  
 
 4.3. Intracellular localization of sialin in primary neuronal cultures 
The intracellular localization of endogenous as well the over-expressed sialin 
was studied in mouse primary hippocampal and cortical neurons and glial cells 
by confocal immunofluorescence microscopy. In neurons, the endogenous 
protein was detectable by this method after 8 div. Interestingly, sialin was 
detected in small vesicles which did not co-localize with a lysosomal marker. 
These vesicles were seen in the cell soma as well as along the axons and the 
dendrites. The axonal expression was observed to increase with time in culture 
as the neurons polarized. The identity of these vesicles is not currently known 
but they did not show co-localization with synaptic vesicles, the endoplasmic 
reticulum, the ER-Golgi intermediate compartment or early endosomes. 
Additionally, sialin was seen in axonal growth cones and in nonpermeabilized 
cells in the plasma membrane. Neuronal plasma membrane expression has also   58
recently been demonstrated for the amino acid transporter LYAAT1, which 
localizes to lysosomes in non-neuronal cells (Wreden et al. 2003). This protein 
is observed also in axonal processes and has been suggested to have a role in 
the exocyst complex which mediates the fusion of secretory vesicles at the 
plasma membrane (Finger and Novick 1998). The exocyst localizes near the 
synaptic vesicles and has a punctuate distribution in the processes of cultured 
hippocampal neurons (Hsu et al. 1996). Intriguingly, components of the exocyst 
complex are seen in the growth cone (Hazuka et al. 1999) where also sialin 
could be detected. This would suggest involvement of sialin in the complex 
secretory processes occuring in neurons. 
A neuronal non-lysosomal localization has also been observed for CLN3 and 
PPT1, the proteins defective in Batten disease and infantile neuronal ceroid 
lipofuscinosis (INCL), respectively. Both of these proteins localize to 
lysosomes in non-neuronal cells but show a different distribution in neurons 
(Hellsten et al. 1996; Jarvela et al. 1998; Lehtovirta et al. 2001; Luiro et al. 
2001). More specificly, CLN3 is localized in the synaptosomes along the 
neuritic extensions and has been suggested a possible role in the neuronal 
endocytosis or exocytosis (Luiro et al. 2001). PPT1 has been shown to localize 
into synaptosomes and synaptic vesicles and has been closely connected to 
neuronal development and synaptogenesis (Hellsten et al. 1996; Isosomppi et al. 
1999; Lehtovirta et al. 2001). 
In glial cells the endogenous sialin could not be detected by 
immunofluorescence. This is probably due to a lower expression level of sialin 
in these cells when compared to primary neurons. The over-expressed protein 
was observed along the endosomal-lysosomal pathway co-localizing with 
lysosomes and also partially with a marker (LBPA) for late endosomes and 
lysosomes. This could suggest a different function or possibly a different 
substrate specificity for sialin in glial cells compared to neurons. If this holds, it   59
might provide a new view to the molecular background of the CNS symptoms 
in SD and ISSD. 
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CONCLUDING REMARKS 
 
Salla disease and ISSD are lysosomal storage diseases in which free sialic acid 
accumulates in most tissues but yet the most severe symptoms manifest in the 
CNS. This thesis was inspired by the desire to elucidate the molecular 
mechanisms underlying these neurodegenerative disorders. 
 
The underlying biochemical defect had earlier been characterized but despite of 
persistent efforts, the gene remained unidentified. With the help of sequence 
information provided by Human Genome Project, the disease-causing gene, 
SLC17A5, was finally identified in this thesis work. A wide variety of mutations 
were detected in both SD and ISSD patients, but in all the Finnish SD patients, 
a founder mutation (SallaFIN) was found. These findings are the basis for 
molecular genetic diagnostics of SD and ISSD, and for example the detection of 
the SallaFIN mutation is currently in routine use in Finland. A genotype-
phenotype correlation was suggested, which was also reflected to the cellular 
level, as the efficiency of the lysosomal targeting of overexpressed sialin was 
severely deficient in polypeptides carrying an ISSD mutation but markedly less 
affected in polypeptides with the SallaFIN mutation.  
 
This work has also provided the starting point and tools to study and analyze the 
cell biology of sialin. Towards this goal, initial analyses of its intracellular 
trafficking were demonstrated here. Interestingly, contrary to non-neuronal 
cells, sialin was not detected in the lysosomes in cultured primary neurons. 
Instead, its localization in neuronal extensions and in growth cones suggests a 
function specific to neuronal processes. Analyses of the neuronal function(s) of 
sialin will be an interesting area of future studies, which should give new   61
perspectives not only into the importance of this protein in neuronal processes 
but also into neuronal metabolism in general. The expression and distribution of 
sialin in mouse brain showed a good correlation with those brain regions most 
affected in SD patients, but the generation of a knockout mouse model will be 
necessary to enable more specific analyses of the CNS pathology in SD and 
ISSD. 
 
The results of this thesis provide a firm basis towards understanding the 
molecular pathogenesis of free sialic acid storage diseases. The significance of 
our findings needs further investigation and more studies have to be conducted 
to unravel the underlying molecular mechanisms. Whether the lysosomal 
accumulation of free sialic acid per se causes the symptoms in SD and ISSD or 
leads to more general disturbances in cellular processes, still remains an open 
question. The combination of the efficient use of bioinformatic tools to analyze 
the enormous amount of genome information available in the databases with 
careful analyses of animal models, should give a way to elucidate the molecular 
mechanisms leading to severe, neurodegenerative free sialic acid storage 
disorders. 
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